Zanamivir

Generic Name: Zanamivir

Brand Names: Relenza, Dectova

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₀N_₄O_₇

CAS Number: 139110-80-8

Unique Ingredient Identifier: L6O3XI777I

Background: A guanido-neuraminic acid that is used to inhibit neuraminidase.

Indication: For the prevention and treatment of influenza A and B.

Associated Conditions: Flu caused by Influenza

Associated Therapies: -

Clinical Trials

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Phase 2

Recruiting

Conditions: Influenza
Influenza, Human

Interventions: Drug: Oseltamivir and Baloxavir
Drug: Oseltamivir and Favipiravir
Drug: Favipiravir and Baloxavir
Drug: Oseltamivir
Drug: Favipiravir
Drug: Zanamivir
Drug: Baloxavir
Drug: Peramivir
Drug: Laninamivir
Drug: Molnupiravir

First Posted Date: 2022-12-13

Last Posted Date: 2024-10-17

Lead Sponsor: University of Oxford

Target Recruit Count: 3000

Registration Number: NCT05648448

Locations: 🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦
Laos-Oxford-Mahosot Wellcome Trust Research unit, Vientiane, Lao People's Democratic Republic
🇳🇵
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal

and more 1 locations

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Zanamivir

First Posted Date: 2021-04-30

Last Posted Date: 2024-10-31

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 14

Registration Number: NCT04867707

Locations: 🇺🇸
University of Missouri, School of Medicine Clinical Research Center, Columbia, Missouri, United States

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

Phase 2

Recruiting

Conditions: Dengue Fever

Interventions: Other: Placebo
Drug: Zanamivir

First Posted Date: 2020-10-22

Last Posted Date: 2024-06-21

Lead Sponsor: George Washington University

Target Recruit Count: 74

Registration Number: NCT04597437

Locations: 🇨🇴
Clinica de la Costa SAS, Barranquilla, Colombia

An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

Phase 2

Recruiting

Conditions: Arthralgia
Influenza, Human

Interventions: Drug: Zanamivir

First Posted Date: 2020-07-31

Last Posted Date: 2024-01-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT04494412

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Drug: Zanamivir

First Posted Date: 2015-03-03

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT02377401

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China

Phase 3

Completed

Conditions: Influenza A Virus Infection
Influenza B Virus Infection

Interventions: Drug: Zanamivir
Drug: Placebo

First Posted Date: 2011-10-25

Last Posted Date: 2013-01-16

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 298

Registration Number: NCT01459081

Locations: 🇨🇳
The Third Xiangya Hospital Of Central South University, Changsha, China
🇨🇳
The First People's Hospital of Hangzhou, Hangzhou, China
🇨🇳
The Affiliated Hospital of Inner Mongolia Medical College, Huhehaote, China

and more 9 locations

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Drug: Zanamivir
Drug: Placebo to match zanamivir
Drug: Placebo to match oseltamivir
Drug: Oseltamivir

First Posted Date: 2010-11-01

Last Posted Date: 2018-10-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 626

Registration Number: NCT01231620

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

Relenza® Sentinel Site Monitoring Program in Japan

Completed

Conditions: Influenza, Human

Interventions: Drug: zanamivir

First Posted Date: 2010-09-13

Last Posted Date: 2017-07-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1575

Registration Number: NCT01199744

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

Phase 1

Completed

Conditions: Influenza A Virus, H1N1 Subtype

Interventions: Drug: Zanamivir

First Posted Date: 2009-10-05

Last Posted Date: 2017-06-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT00989404

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection

Phase 3

Terminated

Conditions: Upper Respiratory Tract Infection
Influenza

Interventions: Drug: Zanamivir
Drug: Placebo of Oseltamivir
Drug: Oseltamivir

First Posted Date: 2009-09-18

Last Posted Date: 2011-04-11

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 4

Registration Number: NCT00979667

Locations: 🇭🇰
Sai Ying Pun Jockey Club General Outpatient Clinic, Hong Kong, Hong Kong
🇨🇳
Shau Kei Wan Jockey Club Clinic, Hong Kong, Hong Kong, China
🇭🇰
Fanling Family Medicine Centre, Hong Kong, Hong Kong

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy